HER2-positive breast cancer is lost in translation: time for patient-centered research.

about

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Increased autophagy blocks HER2-mediated breast tumorigenesis.Targeting the cell cycle in breast cancer: towards the next phase

P2860

Q49843607-0D9DA648-C269-4177-847D-8FF67B2A77EA Q52611925-E2ED1A04-BD22-47DC-9D5F-F2FB7B075199 Q57115037-3AB291DA-7D96-4709-BCB8-10777653DCEC

P2860

HER2-positive breast cancer is lost in translation: time for patient-centered research.

Item

http://www.wikidata.org/entity/Q38648765

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

HER2-positive breast cancer is lost in translation: time for patient-centered research.

@en

type

Item

label

HER2-positive breast cancer is lost in translation: time for patient-centered research.

@en

prefLabel

HER2-positive breast cancer is lost in translation: time for patient-centered research.

@en

P1476

HER2-positive breast cancer is lost in translation: time for patient-centered research.

@en

P2093

Géraldine Gebhart

http://www.w3.org/2001/XMLSchema#string

Isabelle Gingras

http://www.w3.org/2001/XMLSchema#string

Martine Piccart-Gebhart

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Mutational processes molding the genomes of 21 breast cancers

Sharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors

Why your preferred targeted drugs may become unaffordable

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

P31

scholarly article

P356

10.1038/NRCLINONC.2017.96

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Evandro de Azambuja

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28762384

http://www.w3.org/2001/XMLSchema#string

HER2-positive breast cancer is lost in translation: time for patient-centered research.

about

P2860

P2860

HER2-positive breast cancer is lost in translation: time for patient-centered research.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698